Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications "SAVOR- TIMI 53"

Completed

Phase 4 Results

Summary of Purpose

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 July 2014.

1 May 2010 25 Mar 2010 1 May 2013 1 May 2013 1 Jul 2014 15 May 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • AstraZeneca Clinical Study Information

    800-236-9933